Authors : Shamal S. Chand; Nishal Murthi

Volume/Issue : Volume 10 - 2025, Issue 9 - September

Google Scholar : https://tinyurl.com/5a62y8hd

Scribd : https://tinyurl.com/msjsjfcv

DOI : https://doi.org/10.38124/ijisrt/25sep1217

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Recurrent and metastatic cervical cancer (R/M CC) presents a significant clinical challenge, with limited efficacy from conventional therapies such as chemotherapy and radiation. In recent years, antibody-based therapies have emerged as a promising frontier in oncology, offering targeted and personalized treatment strategies. This review explores the evolving role of antibody therapeutics in the management of R/M CC, focusing on immune checkpoint inhibitors (ICIs), antibody-drug conjugates (ADCs), and targeted monoclonal antibodies. ICIs such as pembrolizumab and ipilimumab have demonstrated potential in restoring anti-tumor immunity, although their use is often complicated by immune-related adverse events. ADCs like tisotumab vedotin offer precision delivery of cytotoxic agents, minimizing systemic toxicity. Additionally, anti-angiogenic agents such as bevacizumab and novel antibody formats—including bispecific antibodies and antibody fragments—are expanding the therapeutic landscape. While these approaches show promise, variability in patient response and safety profiles underscores the need for further clinical investigation. This review highlights current advancements, challenges, and future directions in antibody-based therapies for R/M CC, emphasizing the importance of biomarker-driven strategies and combination regimens to optimize clinical outcomes.

References :

1. Alsaab, H. O., et al., 2017. PD-1 and PD-L1 checkpoint signalling inhibition for cancer immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front Pharmacol [online], 8, 561.  DOI:10.3389/fphar.2017.00561 [Accessed 19 October 2023].
2. Azarov, I., et al., 2022. Elaborating on anti-CTLA-4 mechanisms of action using an agent-based modelling approach. Frontiers in Applied Mathematics and Statistics, [online] 8, 993581. DOI:10.3389/fams.2022.993581 [Accessed 24 October 2023].
3. Chung, H. C., et al., 2019. Efficacy and Safety of Pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol, [online] 37(17), 1470-1478. DOI:10.1200/jco.18.01265 [Accessed 17 October 2023].
4. Coleman, R. L., et al., 2021. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncology, [online] 22(5), 609-619.  DOI:10.1016/S1470-2045(21)00056-5 [Accessed 27 October 2023].
5. Fogt, S., et al., 2023. Final results of a phase II trial of prolgolimab with platinum-based therapy and bevacizumab in patients with advanced cervical cancer. Journal of Clinical Oncology, [online] 41(16_suppl), 5536-5536. DOI:10.1200/JCO.2023.41.16_suppl.5536 [Accessed 21 October 2023].
6. Grau-Bejar, J. F., et al., 2023. Advances in immunotherapy for cervical cancer. Ther Adv Med Oncol, [online] 15, 17588359231163836.  DOI:10.1177/17588359231163836 [Accessed 20 October 2023].
7. Hertlein, L., et al.,  2011. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients. Archives of Gynecology and Obstetrics, [online] 283(1), 109-113. DOI:10.1007/s00404-010-1389-1 [Accessed 27  October 2023].
8. Jin, S., et al., 2022. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduction and Targeted Therapy, [online] 7(1), 39. DOI:10.1038/s41392-021-00868-x [Accessed 27 October 2023].
9. Karpathiou, G., et al., 2020. The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix. Pathology-Research and Practice, [online] 216(1), 152782. DOI:10.1016/j.prp.2019.152782 [Accessed 24 October 2023].
10. Karpel, H. C., Powell, S. S., and Pothuri, B. (2023). Antibody-Drug Conjugates in Gynecologic Cancer. American Society of Clinical Oncology Educational Book [online], 43, e390772.  DOI:10.1200/edbk_390772 [Accessed 24 October 2023].
11. Kim, E. S., and Al-Salama, Z. T., 2022. Tisotumab vedotin-tftv in previously treated recurrent or metastatic cervical cancer: a profile of its use in the USA. Drugs & Therapy Perspectives, [online] 38(9), 382-388. DOI:10.1007/s40267-022-00939-1 [Accessed 27 October 2023].
12. Lheureux, S., et al., 2018. Association of ipilimumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus–related cervical carcinoma. JAMA Oncology, [online], 4(7), e173776-e173776. DOI:10.1001/jamaoncol.2017.3776 [Accessed 20 October 2023].
13. Lu, J., Ding, J., Liu, Z., and Chen, T. 2022. Retrospective analysis of the preparation and application of immunotherapy in cancer treatment. International Journal of Oncology, [online], 60(2), 1-23.  DOI:10.3892/ijo.2022.5302 [Accessed 27 October 2023].
14. Monk, B. J., et al., 2023. KEYNOTE-826: Final overall survival results from a randomised, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. Journal of Clinical Oncology, [online] 41(16_suppl), 5500-5500.  DOI:10.1200/JCO.2023.41.16_suppl.5500 [Accessed 27 October 2023].
15. Monk, B. J., et al., 2022. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials. Cancer Treatment Reviews, [online] 106, 102385.  DOI:10.1016/j.ctrv.2022.102385 [Accessed 29 October 2023].
16. Muraro, E., et al., 2021. Cetuximab in locally advanced head and neck squamous cell carcinoma: Biological mechanisms involved in efficacy, toxicity and resistance. Critical Reviews in Oncology/Hematology, [online], 164, 103424.  DOI:10.1016/j.critrevonc.2021.103424 [Accessed 29 October 2023].
17. Naumann, R. W., et al., 2019. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial. Journal of Clinical Oncology, [online], 37(31), 2825.  DOI:10.1200/JCO.19.00739 [Accessed 29 October 2023].
18. O’Malley, D. M., et al., 2021. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. Gynecologic Oncology, [online], 163(2), 274-280.  DOI:10.1016/j.ygyno.2021.08.018 [Accessed 29 October 2023].
19. O’Malley David, M., and Calo, C. A., 2021. Progress in gynecologic cancers with antibody drug conjugates. Current Oncology Reports, [online] 23(8). DOI:10.1007/s11912-021-01080-4 [Accessed 27 October 2023].
20. Oaknin, A., et al., 2022. 520MO Safety and efficacy of nivolumab (NIVO)±ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358. Annals of Oncology, [online] 33, S782.  DOI:10.1016/j.annonc.2022.07.648 [Accessed 20 October 2023].
21. Ordóñez-Reyes, C., et al., 2022. Bispecific antibodies in cancer immunotherapy: A novel response to an old question. Pharmaceutics, [online], 14(6).  DOI:10.3390/pharmaceutics14061243 [Accessed 24 October 2023].
22. Pang, X., et al., 2023. Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity. mABs, [online], 15(1), 1-16.  DOI:10.1080/19420862.2023.2180794  [Accessed 29 October 2023]
23. Santin, A. D., et al., 2020. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecologic Oncology, [online], 157(1), 161-166.  DOI:10.1016/j.ygyno.2019.12.034 [Accessed 19 October 2023].
24. Scott, A. M., Wolchok, J. D., and Old, L. J., 2012. Antibody therapy of cancer. Nature reviews cancer. [online], Available at: https://www.roswellpark.org/sites/default/files/hernandez_4-4-17_article_2.pdf [Accessed 28 October 2023].
25. Sobhani, N., et al.,  2021. CTLA-4 in regulatory T cells for cancer immunotherapy. Cancers (Basel), [online], 13(6).  DOI:10.3390/cancers13061440 [Accessed 24 October 2023].
26. Strauss, J., et al., 2020. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies. Journal for ImmunoTherapy of Cancer, [online], 8(2), e001395.  DOI:10.1136/jitc-2020-001395 [Accessed 24 October 2023].
27. Sun, Y., et al., 2023. Bispecific antibodies in cancer therapy: Target selection and regulatory requirements. Acta Pharm Sin B, [online], 13(9), 3583-3597.  DOI:10.1016/j.apsb.2023.05.023 [Accessed 18 October 2023].
28. Sung, H., et al., 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, [online], 71(3), 209-249.  DOI:10.3322/caac.21660 [Accessed 20 October 2023].
29. Tewari, K. S., et al., 2022. Survival with cemiplimab in recurrent cervical cancer. New England Journal of Medicine, [online], 386(6), 544-555. DOI:10.1056/NEJMoa2112187 [Accessed 24 October 2023].
30. Tewari, K. S., et al., 2014. Improved survival with bevacizumab in advanced cervical cancer. [online], New England Journal of Medicine, 370(8), 734-743. DOI:10.1056/NEJMoa1309748 [Accessed 24 October 2023].
31. Tewari, K. S., et al., 2017. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet, [online], 390(10103), 1654-1663. DOI:10.1016/s0140-6736(17)31607-0 [Accessed 20 October 2023].
32. Tomao, F., et al., 2022. Angiogenesis and antiangiogenic agents in cervical cancer. OncoTargets and therapy,  [online], 2237-2248. DOI: 10.2147/OTT.S68286 [Accessed 20 October 2023].
33. Urwyler, P., et al., 2020. Mechanisms of checkpoint inhibition-induced adverse events. Clin Exp Immunol, [online], 200(2), 141-154. DOI:10.1111/cei.13421 [Accessed 20 October 2023].
34. Ventola, C. L. (2017). Cancer immunotherapy, Part 2: Efficacy, safety, and other clinical considerations. National Library of Medicine, [online], 42(7), 452-463. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481296/ [Accessed 21 October 2023].
35. Vergote, I., et al., 2023. Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: Results from the innovaTV 205/GOG-3024/ENGOT-cx8 Study. Journal of Clinical Oncology, [online], 1(1), JCO.23.00720. DOI: 10.1200/jco.23.00720 [Accessed 20 October 2023].
36. Xie, Y.-H., et al., 2020. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduction and Targeted Therapy, [online],  5(1), 22. DOI: 10.1038/s41392-020-0116-z [Accessed 22 October 2023].
37. Xie, Y., et al., 2022. Immune checkpoint inhibitors in cervical cancer: Current status and research progress. Front Oncology, [online], 12, 984896. https://doi.org/10.3389/fonc.2022.984896 [Accessed 28 October 2023].
38. Zhao, X., et al., 2018. Expression of tissue factor in human cervical carcinoma tissue. Experimental and Therapeutic Medicine, [online], 16(5), 4075-4081. https://doi.org/doi.org/10.3892/etm.2018.6723 [Accessed 23 October 2023].
39. Zhao, Y., et al., 2023. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors. Journal of Hematology & Oncology, [online], 16(1), 50. https://doi.org/10.1186/s13045-023-01445-1 [Accessed 22 October 2023].